Wolfe Research reiterates Peerperform on Biogen stock after trial miss By Investing.com

Biogen’s phase 2 CELIA study for diranersen missed its primary endpoint, but showed reductions in tau biomarkers and cognitive benefit signals across doses, prompting the company to advance the drug into late-stage development. Wolfe Research reiterated a Peerperform rating, while other brokers remained constructive; Biogen also trades near its 52-week high at $204.53 after a nearly 70% gain over the past year. The news is mixed for the stock, but the continued Alzheimer’s pipeline progress should keep BIIB in focus.

Analysis

The market is starting to price BIIB less as a binary Alzheimer’s readout and more as a platform with multiple shots on goal. The key second-order effect is that even a failed primary endpoint can be enough to reset the optionality if biomarker suppression and cognitive signal persist; that tends to keep strategic value elevated and compresses downside from the old “one-done” Alzheimer’s failure pattern. In practice, this shifts the stock from event-risk driven to expectation-management driven over the next 3-6 months, with late-stage program advancement becoming the main catalyst.

The bigger winner may be not BIIB’s near-term revenue base, but the whole anti-amyloid/anti-tau ecosystem: contract researchers, imaging vendors, and competing CNS platforms now have a more credible proof point that tau modulation can show human signal in placebo-controlled settings. That raises the bar for rivals that are still purely biomarker-led, and it may pull capital toward companies with clearer mechanistic readthrough rather than broad neurodegeneration baskets. At the same time, higher serious adverse events at the top dose create a natural ceiling on enthusiasm; the commercial path likely depends on a lower-dose regimen, which can blunt peak-sales expectations versus the most bullish Alzheimer’s models.

The contrarian miss here is that the upside may be more muted than the headline optimism suggests because the Alzheimer’s market is already crowded with “promising but imperfect” assets. If lecanemab-related timing uncertainty persists, BIIB could get another sentiment boost, but that is more a window for multiple expansion than a step-change in fundamentals. Over 6-12 months, the stock’s biggest risk is a replay of the same pattern: good biomarker story, equivocal clinical utility, and gradual mean reversion once the next catalyst passes.

Key Decisions for Investors

• Stay long BIIB into the next 1-3 month catalyst window, but hedge with out-of-the-money puts; the setup favors a sentiment squeeze, yet single-study disappointment risk remains high. Best risk/reward is to own the equity and cap downside into any regulator or late-stage update.
• Pair trade: long BIIB / short a basket of pure-play CNS names with weaker biomarker support over the next 3-6 months. The thesis is that capital will continue to migrate toward programs with human tau readthrough, while weaker assets lose relative support.
• If BIIB gaps higher on follow-through commentary, trim into strength rather than chase above recent highs; upside from here is likely multiple expansion, not a full re-rating of long-term Alzheimer’s economics. Use $205-$215 as a discipline zone for profit-taking.
• For more convex exposure, consider BIIB call spreads 3-6 months out rather than outright calls. The trade is designed for a moderate re-rating with limited premium burn if the market quickly fades the newsflow.
• Watch for any update on lecanemab timing or late-stage diranersen design; if either becomes cleaner, add on dips rather than momentum entries. Those are the only catalysts likely to extend the move beyond a 2-4 week trading bounce.